

Principal Pharmaceuticals & Chemicals Ltd.
4, Amrapali, Turel Pakhadi Road, Near Liberty Garden, Malad West, Mumbai - 400 064
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2008

Rs. In lacs except EPS

Sr. No.		3 Months ended 30th June, 2008 Un-Audited	3 Months ended 30th June, 2007 Un-Audited	Previous Year 2007-08 Audited
1	Net Sales/Income from operations	15.65	6.00	25.50
2	Other Income	-	-	24.27
	Total Income	15.65	6.00	49.77
3	Total Expenditure			
a.	(Increase)/decrease in stock trade	-	-	-
b.	Consumption of raw materials	-	-	-
c.	Staff Cost	0.01	0.02	0.07
d.	Power & Fuel & Oil	-	-	-
e.	Job processing charges	-	-	-
f.	Internet Business Development Cost	-	0.73	1.05
g.	Other expenditure	1.84	2.86	7.01
4	Interest	-	-	-
5	Depreciation & Amortisation	8.38	9.24	36.86
6	Profit/(Loss) before tax (1+2-3-4-5)	5.42	(6.85)	4.78
	Less :			
7	Interest for earlier years			13.52
8	Provision for taxation			-
	- Current Year Tax	-	-	-
	- Deferred Tax	-	-	-
	- Fringe Benefit Tax	0.03	-	0.07
9	Net Profit/(Loss) (6-7)	5.39	(6.85)	(8.81)
	Extraordinary Items			
10	Add : Credits due to restructured liabilities	-	-	314.99
11	Balance carried to the balance sheet	5.39	(6.85)	306.18
12	Paid-up equity share capital (Face value Rs 10/- each)	599.97	599.97	599.97
13	Reserve excluding revaluation reserves (Net of debit balance of Profit & Loss Account)			(510.77)
14	Basic & diluted EPS for the period, for the year to date & for the previous year	0.09	(0.11)	(0.15)
15	Annualised	0.36	(0.46)	(0.15)
16	Aggregate of Non-Promoters' Shareholding			
	No. of shares (in lacs)	40.79	40.79	40.79
	Percentage of Shareholding	67.99%	67.99%	67.99%

1 The company has two segment from this quarter viz. eCommerce Consulting & Pharmaceuticals & Intermediates. Segment wise details are as under :

	3 Months ended 30th June, 2008	3 Months ended 30th June, 2007	Rs. in lacs Audited 2007-08
Income :			
i. eCommerce Consulting	12.65	-	-
ii. Pharmaceuticals & Intermediates	3.00	6.00	49.77
Expenditure (including Depreciation) :			
i. eCommerce Consulting	1.50	-	-
ii. Pharmaceuticals & Intermediates	8.76	12.85	58.58
Net Profit / (Loss)			
i. eCommerce Consulting	11.15	-	-
ii. Pharmaceuticals & Intermediates	(5.76)	(6.85)	(8.81)

2 The Company was declared as "Sick Company" by the Board for Industrial & Financial Reconstruction u/s 3(1)(o) of Sick Industrial Companies (Special Provision) Act,1985. An order to that effect was received by the company in October, 2005. According to the directives, the company prepared and submitted Rehabilitation cum One Time Settlement proposal to the respective Bank and FI and to BIFR. The company has settled & paid dues to one of the Banks in the year 2006-07. The settlement with FI has also been approved and based on their approval, the settled amount is being paid. However, one bank has issued notice under Sec. 13(2) of the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 which has been objected by the company.

3 BSE has not yet revoked the suspension order though the company has complied with all the provisions of the listing agreement and paid listing fee upto March, 2009.

4 There were no complaints pending at the beginning of 1st Quarter . Complaints received during 1st Quarter - NIL; Complaints solved during 1st Quarter - NIL; Complaints pending at the end of 1st Quarter - NIL.

5 The above results have been reviewed and taken on record at the meeting of the Audit Committee and the Board of Directors held on 31st July, 2008.

By Order of the Board

Place : Mumbai
Dated : 31st July, 2008

Pradeep Malu
President & CEO